These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24340569)

  • 21. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Financing of certified centers: a willingness-to-pay analysis.
    Thiel FC; Scharl A; Hildebrandt T; Kotziabassis E; Schrauder MG; Bani MR; Müller A; Hauzenberger T; Loehberg CR; Jud SM; Fasching PA; Hartmann A; Schulz-Wendtland R; Strnad V; Beckmann MW; Lux MP
    Arch Gynecol Obstet; 2013 Mar; 287(3):495-509. PubMed ID: 23080545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incremental cost effectiveness evaluation in clinical research.
    Krummenauer F; Landwehr I
    Eur J Med Res; 2005 Jan; 10(1):18-22. PubMed ID: 15737949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hospital reimbursement incentives: is there a more effective option?--Part II.
    Weil TP
    J Med Pract Manage; 2013; 28(4):254-6. PubMed ID: 23547503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
    Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic considerations for the hepatologist.
    Provenzale D
    Hepatology; 1999 Jun; 29(6 Suppl):13S-17S. PubMed ID: 10386077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Out-of-network charges out of this world.
    Manag Care; 2013 May; 22(5):16. PubMed ID: 23757829
    [No Abstract]   [Full Text] [Related]  

  • 31. An extreme makeover for the employer's house of health benefits.
    Boress LS
    J Leg Med; 2011 Jan; 32(1):51-60. PubMed ID: 21391055
    [No Abstract]   [Full Text] [Related]  

  • 32. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decision makers' views on health care objectives and budget constraints: results from a pilot study.
    Al MJ; Feenstra T; Brouwer WB
    Health Policy; 2004 Oct; 70(1):33-48. PubMed ID: 15312708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The "cost reimbursement" trial regulation in mandatory health insurance: results of a survey of participants].
    König HH; Seitz R; Arnold M
    Gesundheitswesen; 1999 Jan; 61(1):13-9. PubMed ID: 10081181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The devil's in the details: trading policy goals for complexity in medicaid nursing home reimbursement.
    Miller EA; Mor V; Grabowski DC; Gozalo PL
    J Health Polit Policy Law; 2009 Feb; 34(1):93-135. PubMed ID: 19234295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Economic feasibility study and reimbursement rules--illustrated by a concrete example].
    Keiding H; Faergeman O
    Ugeskr Laeger; 2008 Feb; 170(8):651-4. PubMed ID: 18364159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Are diagnostic codes in accordance with the SGB V regulation and classification of case fees and special charges a suitable instrument for controlling costs in surgery?].
    Ziegler M
    Langenbecks Arch Chir Suppl Kongressbd; 1997; 114():785-7. PubMed ID: 9574268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phone fees: a justification of physician charges.
    Braithwaite SS; Unferth NO
    J Clin Ethics; 1993; 4(3):219-24. PubMed ID: 8219306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.